News Conference News ACC 2023 HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension Todd Neale March 08, 2023
News Conference News CRT 2023 Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months Yael L. Maxwell February 28, 2023
News Conference News TCT 2022 SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss Michael O'Riordan September 19, 2022
News Conference News ACC 2022 QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis L.A. McKeown April 07, 2022
News Conference News ACC 2022 Bentracimab Swiftly Reverses Ticagrelor, Platelet-Function Study Affirms Todd Neale April 02, 2022
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Conference News SCAI 2021 ISCHEMIA: PCI/CABG Has Early Hospitalization ‘Tax’ but Equals Meds Later Michael O'Riordan May 06, 2021
News Conference News AHA 2020 Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials Michael O'Riordan November 17, 2020
News Conference News AHA 2020 FIDELIO-DKD: Finerenone Cuts CV Events in Diabetic Kidney Disease Todd Neale November 16, 2020
News Conference News AHA 2020 Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT Todd Neale November 15, 2020
News Conference News ACC 2020 Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT Todd Neale April 02, 2020
News Conference News ACC 2020 Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach Todd Neale March 28, 2020
News Conference News ESC 2019 Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS Michael O'Riordan September 01, 2019
News Conference News ACC 2019 REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events Yael L. Maxwell March 22, 2019
News Conference News ACC 2019 Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom Michael O'Riordan March 20, 2019
News Conference News CRT 2019 Renal Denervation With Alcohol Infusions Appears Safe, but Clinical Impact Remains Unproven Yael L. Maxwell March 06, 2019
News Conference News AHA 2018 Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study Michael O'Riordan November 15, 2018
News Conference News AHA 2018 REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides Todd Neale November 10, 2018
News Conference News AHA 2018 VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer Shelley Wood November 10, 2018